Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014

ResearchMoz include new market research report"Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports.

Logo

Albany, NY -- (ReleaseWire) -- 04/14/2014 --Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Small Cell Lung Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

View Full Report With Complete TOC at http://www.researchmoz.us/non-small-cell-lung-cancer-global-clinical-trials-review-h1-2014-report.html

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Browse Other Published Reports by Globaldata at http://www.researchmoz.us/publisher/globaldata-1.html

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Related Reports -

PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

View Full Report at http://www.researchmoz.us/pharmapoint-non-small-cell-lung-cancer-china-drug-forecast-and-market-analysis-to-2022-report.html

PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

View Full Report at http://www.researchmoz.us/pharmapoint-non-small-cell-lung-cancer-france-drug-forecast-and-market-analysis-to-2022-report.html

PharmaPoint: Non-Small Cell Lung Cancer - Germany Drug Forecast and Market Analysis to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

View Full Report at http://www.researchmoz.us/pharmapoint-non-small-cell-lung-cancer-germany-drug-forecast-and-market-analysis-to-2022-report.html

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Website@ http://www.researchmoz.us/
Email: sales@researchmoz.us

Browse Blog - http://pramoddige91.wordpress.com/

Media Relations Contact

Sheela AK
Business Head
ResearchMoz
518-618-1030
http://www.researchmoz.us

View this press release online at: http://rwire.com/492846